|
HOTopics Webinar Rescheduled to
February 9, 2011
New Cytotoxic Chemotherapy Agents Approved for Metastatic Breast Cancer and Hormone Refractory Prostate Cancer
Join us for this Webinar on February 9, 1-2 pm CST
Space is limited. Reserve your Webinar seat now at:
https://www3.gotomeeting.com/register/134217470
After registering you will receive a confirmation email containing information about joining the Webinar.
Topic One: Eribulin Improves Overall Survival as a Third Line Agent in Metastatic Breast Cancer
Speaker: Michael J. Berger, PharmD
Speciality Practice Pharmacist
The Arthur G. James Cancer Hospital
Objectives:
1. Describe the role of eribulin in the treatment of metastatic breast cancer.
2. Discuss the need for dosage adjustment for hepatic and renal impairment.
3. Illustrate the appropriate management of the dose limiting toxicities identified for eribulin.
Topic Two: Cabazitaxel as a Second Line Agent for Hormone Refractory Prostate Cancer
Speaker: Sherry L. Mori Vogt, PharmD
Speciality Practice Pharmacist
The Arthur G. James Cancer Hospital
Objectives:
1. Describe the role of cabazitaxel in the treatment of hormone refractory prostate cancer.
2. Discuss the appropriate dosage for cabazitaxel in combination with prednisone.
3. Illustrate the appropriate management of the serious adverse events associated with cabazitaxel.
|
